[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586935":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":31,"responsibleParty":192,"collaborators":19,"id":194,"slug":19,"hasResults":195,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":19,"eligibilityCriteria":199,"healthyVolunteers":195,"sex":200,"minAge":201,"maxAge":202,"enrollmentInfo":203,"targetDuration":19,"studyType":206,"phases":207,"briefSummary":209,"conditions":210,"keywords":212,"overallStatus":34,"whyStopped":19,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":224},{"fullName":5,"class":6},"UCB Pharma","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Bimekizumab","EXPERIMENTAL","Study participants will receive a bimekizumab dose which is weight-dependent.",[13],"Drug: Bimekizumab",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Bimekizumab will be administered at pre-specified timepoints.",[9],null,[21],{"name":22,"affiliation":23,"role":24},"UCB Cares","001 844 599 2273","STUDY_DIRECTOR",[26,30],{"name":22,"role":27,"phone":28,"phoneExt":19,"email":29},"CONTACT","+18445992273","ucbcares@ucb.com",{"name":22,"role":27,"phone":23,"phoneExt":19,"email":19},[32,45,55,65,75,85,95,105,109,118,128,138,148,157,165,174,179,187],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":19},"Hs0006 50175","RECRUITING","Phoenix","Arizona","85006","United States",{"type":40,"coordinates":41},"Point",[42,43],-112.07404,33.44838,{"lat":43,"lon":42},{"facility":46,"status":34,"city":47,"state":48,"zip":49,"country":38,"cosmosGeoPoint":50,"geoPoint":54,"contacts":19},"Hs0006 50708","Roseville","California","95661",{"type":40,"coordinates":51},[52,53],-121.28801,38.75212,{"lat":53,"lon":52},{"facility":56,"status":57,"city":58,"state":48,"zip":59,"country":38,"cosmosGeoPoint":60,"geoPoint":64,"contacts":19},"Hs0006 50684","ACTIVE_NOT_RECRUITING","Sacramento","95815",{"type":40,"coordinates":61},[62,63],-121.4944,38.58157,{"lat":63,"lon":62},{"facility":66,"status":34,"city":67,"state":68,"zip":69,"country":38,"cosmosGeoPoint":70,"geoPoint":74,"contacts":19},"Hs0006 50707","Washington D.C.","District of Columbia","20010",{"type":40,"coordinates":71},[72,73],-77.03637,38.89511,{"lat":73,"lon":72},{"facility":76,"status":34,"city":77,"state":78,"zip":79,"country":38,"cosmosGeoPoint":80,"geoPoint":84,"contacts":19},"Hs0006 50199","Miami","Florida","33136",{"type":40,"coordinates":81},[82,83],-80.19366,25.77427,{"lat":83,"lon":82},{"facility":86,"status":34,"city":87,"state":88,"zip":89,"country":38,"cosmosGeoPoint":90,"geoPoint":94,"contacts":19},"Hs0006 50712","Bowling Green","Kentucky","42104",{"type":40,"coordinates":91},[92,93],-86.4436,36.99032,{"lat":93,"lon":92},{"facility":96,"status":34,"city":97,"state":98,"zip":99,"country":38,"cosmosGeoPoint":100,"geoPoint":104,"contacts":19},"Hs0006 50178","Clarkston","Michigan","48346",{"type":40,"coordinates":101},[102,103],-83.41883,42.73586,{"lat":103,"lon":102},{"facility":106,"status":34,"city":107,"state":98,"zip":108,"country":38,"cosmosGeoPoint":19,"geoPoint":19,"contacts":19},"Hs0006 50710","Fort Gratiot","48059",{"facility":110,"status":34,"city":111,"state":98,"zip":112,"country":38,"cosmosGeoPoint":113,"geoPoint":117,"contacts":19},"Hs0006 50711","Troy","48084",{"type":40,"coordinates":114},[115,116],-83.14993,42.60559,{"lat":116,"lon":115},{"facility":119,"status":34,"city":120,"state":121,"zip":122,"country":38,"cosmosGeoPoint":123,"geoPoint":127,"contacts":19},"Hs0006 50706","Chapel Hill","North Carolina","27516",{"type":40,"coordinates":124},[125,126],-79.05584,35.9132,{"lat":126,"lon":125},{"facility":129,"status":34,"city":130,"state":131,"zip":132,"country":38,"cosmosGeoPoint":133,"geoPoint":137,"contacts":19},"Hs0006 50202","Fairborn","Ohio","45324",{"type":40,"coordinates":134},[135,136],-84.01938,39.82089,{"lat":136,"lon":135},{"facility":139,"status":34,"city":140,"state":141,"zip":142,"country":38,"cosmosGeoPoint":143,"geoPoint":147,"contacts":19},"Hs0006 50201","Arlington","Texas","76011",{"type":40,"coordinates":144},[145,146],-97.10807,32.73569,{"lat":146,"lon":145},{"facility":149,"status":34,"city":150,"state":19,"zip":19,"country":151,"cosmosGeoPoint":152,"geoPoint":156,"contacts":19},"Hs0006 40326","Berlin","Germany",{"type":40,"coordinates":153},[154,155],13.41053,52.52437,{"lat":155,"lon":154},{"facility":158,"status":34,"city":159,"state":19,"zip":19,"country":151,"cosmosGeoPoint":160,"geoPoint":164,"contacts":19},"Hs0006 40747","Mainz",{"type":40,"coordinates":161},[162,163],8.28008,49.98185,{"lat":163,"lon":162},{"facility":166,"status":34,"city":167,"state":19,"zip":19,"country":168,"cosmosGeoPoint":169,"geoPoint":173,"contacts":19},"Hs0006 40625","Warsaw","Poland",{"type":40,"coordinates":170},[171,172],21.01178,52.22977,{"lat":172,"lon":171},{"facility":175,"status":34,"city":167,"state":19,"zip":19,"country":168,"cosmosGeoPoint":176,"geoPoint":178,"contacts":19},"Hs0006 40761",{"type":40,"coordinates":177},[171,172],{"lat":172,"lon":171},{"facility":180,"status":34,"city":181,"state":19,"zip":19,"country":168,"cosmosGeoPoint":182,"geoPoint":186,"contacts":19},"Hs0006 40095","Wroclaw",{"type":40,"coordinates":183},[184,185],17.03006,51.10286,{"lat":185,"lon":184},{"facility":188,"status":34,"city":181,"state":19,"zip":19,"country":168,"cosmosGeoPoint":189,"geoPoint":191,"contacts":19},"Hs0006 40845",{"type":40,"coordinates":190},[184,185],{"lat":185,"lon":184},{"type":193,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100586935",false,"NCT06921850","A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa","A Multicenter, Open-Label Study to Assess The Pharmacokinetics And Safety of Bimekizumab in Pubertal Children And Adolescents With Moderate to Severe Hidradenitis Suppurativa","Inclusion Criteria:\n\n* Study participant must be 12 to \\\u003C18 years of age at the time of informed consent\u002Fassent, at Tanner stage 2 or more, for the first 8 participants only, followed by also including participants ≥9 to \\\u003C18 years of age at Tanner stage 2 or more.\n* Study participant must have a diagnosis of HS for at least 6 months prior to the Baseline Visit.\n* Study participant must have moderate to severe HS, defined as a total of ≥5 inflammatory lesions (ie, the sum of abscesses and inflammatory nodules), as assessed at both the Screening and Baseline Visits.\n* Study participant must have HS lesions present in at least 2 distinct anatomic areas, 1 of which must be at least Hurley Stage II or III, as assessed at both the Screening and Baseline Visits.\n* Study participant must have had a history of inadequate response to a course of a systemic antibiotic for treatment of HS\n* Study participant must weigh ≥30kg at the Screening Visit.\n\nExclusion Criteria:\n\n* Study participant has a draining tunnel count of \\>20 at either the Screening or Baseline Visits.\n* Study participant has experienced primary failure (no response within 12 weeks) to 1 or more IL 17 biologic response modifiers (eg, brodalumab, ixekizumab, secukinumab) OR primary failure to more than 1 biologic response modifier other than an IL-17 biologic response modifier.\n* Study participant has previously participated in this study or has received previous therapy with bimekizumab.\n* Study participant has a history of IBD or symptoms suggestive of IBD.\n* History of active tuberculosis unless successfully treated, latent TB unless prophylactically treated\n* Study participant has an active infection or history of infections (such as serious infection, chronic infections, opportunistic infections, unusually severe infections)\n* Study participant has received drugs outside the specified timeframes relative to the Baseline Visit or receives prohibited concomitant treatments\n* Study participant has the presence of active suicidal ideation, or positive suicide behavior,\n* Study participant diagnosed with severe depression in the past 6 months prior to the Screening Visit.\n* Study participant has a history of psychiatric inpatient hospitalization within the past year before enrolling into the study.","ALL","9 Years","17 Years",{"count":204,"type":205},40,"ESTIMATED","INTERVENTIONAL",[208],"PHASE3","The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)",[211],"Hidradenitis Suppurativa",[9,213,211],"HS","2026-06-18",{"date":216,"type":217},"2026-06-22","ACTUAL",{"date":219,"type":217},"2025-04-07",{"date":221,"type":205},"2029-03-06",{"name":223,"class":6},"UCB Biopharma SRL",18]